Generated by AI
Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for oncology and obesity. Corbus Pharmaceuticals Holdings, Inc. advances a pipeline centered on targeted treatments, including CRB-701, an antibody drug conjugate designed to target Nectin-4 on cancer cells, and CRB-913, a peripherally restricted cannabinoid type-1 receptor inverse agonist being studied for obesity. The company’s work is concentrated on well-defined biological pathways and on creating medicines that address serious diseases through precision-focused mechanisms. Corbus Pharmaceuticals Holdings, Inc. plays a role in the biotechnology market as a developer of investigational drug candidates aimed at cancer and metabolic disease, with its current programs spanning clinical research and product development in these therapeutic areas.
Website500 River Ridge Drive
Norwood, MA, 02062
United States
The latest articles about CRBP.
Summary of Nov 16's posts. Generated by AI.
Summary of Sep 11's posts. Generated by AI.
Summary of Apr 7's posts. Generated by AI.
Summary of Sep 15's posts. Generated by AI.
Investors talking about CRBP also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.